Pancreatic tumor

Can we crack this cancer's immune response?

Retrieved on: 
Wednesday, November 29, 2023
Cold Spring Harbor Laboratory, Pancreatic cancer, Immunity, Antigen, Immune system, Cold, Pancreatic tumor, CSHL, Disease, B cell, Vaccination, Patient, Cancer, PDAC, Northwell Health, Pancreas, Future, Antibody, SPRING, Cell, Vaccine

It's thought patients do not show a natural immune response to the cancer because the tumor environment somehow prevents that response.

Key Points: 
  • It's thought patients do not show a natural immune response to the cancer because the tumor environment somehow prevents that response.
  • Many are unconvinced that PDAC interacts with the immune system at all.
  • CSHL scientists have now confirmed that pancreatic cancer does trigger a response in our immune system.
  • The idea was that the synthetic antibodies would point the team toward the new PDAC antigen behind the body's immune response .

November is Pancreatic Cancer Awareness Month

Retrieved on: 
Wednesday, November 8, 2023
FDA, Holiday, IND, John Engen, Legislation, Pancreatic tumor, EDV, ANDC, Disease, Cancer, Neoplasm, Rivian EDV, Survival rate, Pancreatic cancer, Safety, Oncology, PDAC, Drug resistance, Patient, Drug discovery, Investigational New Drug, Pharmaceutical industry, L.A

EnGeneIC, an Australian/USA biotechnology company, has developed a proprietary targeted nanocell-based therapeutic focused on treatment of low survival solid-tumors, including PDAC.

Key Points: 
  • EnGeneIC, an Australian/USA biotechnology company, has developed a proprietary targeted nanocell-based therapeutic focused on treatment of low survival solid-tumors, including PDAC.
  • The nanocell (designated EDVTM; EnGeneIC Dream Vector) is best described as an Antibody-Nanocell-Drug-Conjugate (ANDC) which also stimulates a powerful anti-tumour immune response.
  • Amazingly, after 15 months of EDV therapy, the patient’s cancer has disappeared and this has been achieved with minimal side effects.
  • In fact, the patient’s quality of life improved so much that she was allowed EDV-treatment breaks for holidays in Paris and Hawaii.

Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board

Retrieved on: 
Friday, November 3, 2023
FDA, Laser capture microdissection, MTB, HER2, OTC, Sheridan, Conference, Inova Health System, NGS, Pancreatic tumor, Partnership, Interim, Pancreatic cancer, Cancer, LCM, Proteomics, Patient, ASCO, Gastrointestinal cancer, Pharmaceutical industry, Medical imaging

The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova’s molecular tumor board’s operational workflow.

Key Points: 
  • The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova’s molecular tumor board’s operational workflow.
  • Over the past year, Inova has undertaken a feasibility study to develop and implement the procedures and infrastructure necessary for proteomic analysis within the context of the Inova Schar Molecular Tumor Board.
  • Interim results of this pan-tumor study were presented at the 2023 ASCO Conference in Chicago.
  • “Theralink is extremely encouraged by the work done to date at Inova Schar Cancer Institute- the interim results and clinical intelligence speak for themselves.

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MDSC, Pancreatic tumor, Pressure, Pancreas, Liver, Perfusion, TLR9, Drug, FACS, SITC, Annual general meeting, Pancreatic cancer, Immunotherapy, TLR, Tumor microenvironment, University, Safety, Society, MD Anderson Cancer Center, Patient, Society for Immunotherapy of Cancer, Medical imaging, Medical device, Pharmaceutical industry, Cancer

In PERIO-03, SD-101 is delivered via PEDD with the TriSalus Infusion System® using a retrograde venous approach, leveraging established interventional radiology access techniques.

Key Points: 
  • In PERIO-03, SD-101 is delivered via PEDD with the TriSalus Infusion System® using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • The TriSalus Infusion System has an expandable SmartValve® and can interface with standard invasive blood pressure transducers for continuous pressure monitoring during infusion of a therapeutic.
  • This is a first-in-human experience for use of PEDD and retrograde venous infusion for delivery of an immunologic agent into pancreatic tumors.
  • We are excited to continue enrolling patients in this study.”
    “These data offer additional validation of our innovative immunotherapy approach for pancreatic tumors.

ENTERTAINMENT HOST AND SURVIVOR, MARIA MENOUNOS, SHARES HOW EARLY DETECTION SAVED HER LIFE IN PANCREATIC CANCER ACTION NETWORK'S NOVEMBER CAMPAIGN

Retrieved on: 
Wednesday, November 1, 2023
Steps, Survival, Pancreatic cancer, Abdominal pain, Intelligence, PSA, Pancreatic Cancer Action Network, Health, JD, Spleen, Lymph, Human, Diarrhea, Pancreas, MBA, Television, Public service announcement, Research, Cancer, Disease, Pancreatic tumor, Risk, PSAS, Breast cancer, LOS, Patient, Diagnosis, Pharmaceutical industry, Medical imaging

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- This November, celebrated media personality, actor, television, and "Heal Squad" podcast host, Maria Menounos, is lending her voice in support of the Pancreatic Cancer Action Network's (PanCAN) annual Pancreatic Cancer Awareness Month campaign, launching today. This year's campaign, titled "Change The Course," underscores the importance of recognizing the key risks and symptoms for early detection of pancreatic cancer. Menounos will be featured in a public service announcement (PSA) calling attention to understanding early signs and symptoms and advocating for your health. Additional digital and broadcast PSAs will run throughout the month, highlighting survivor and caregiver stories that show how early detection can change the course of pancreatic cancer and extend the chances of survival. The campaign will also spotlight the latest early detection initiatives and outreach to higher-risk communities.

Key Points: 
  • This year's campaign, titled "Change The Course," underscores the importance of recognizing the key risks and symptoms for early detection of pancreatic cancer.
  • The campaign will also spotlight the latest early detection initiatives and outreach to higher-risk communities.
  • Pancreatic cancer is the third leading cause of cancer-related deaths in the United States and is on track to become the second leading cause.
  • Currently, there is no standard screening test to detect pancreatic cancer early the way there is for other major cancers like mammograms for breast cancer or colonoscopies for colon cancer.

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

Retrieved on: 
Thursday, October 19, 2023
Neoplasm, Fibroblast, IND, Ovarian cancer, Human, Gastrointestinal cancer, PFS, Conference, TNBC, Tissue, ADC, Pancreatic tumor, Spacecraft, Pancreatic cancer, PDX, FAK, CAF, Pharmaceutical industry, Medical imaging

Meanwhile, one critical factor limiting ADC effectiveness is poor access to tumor cells, especially in high stroma tumors such as pancreatic tumor, TNBC etc.

Key Points: 
  • Meanwhile, one critical factor limiting ADC effectiveness is poor access to tumor cells, especially in high stroma tumors such as pancreatic tumor, TNBC etc.
  • Preclinical data demonstrated that IN10018 was able to break down the fibrotic barrier, improving penetration of large molecules including ADC.
  • Significant synergy was observed between IN10018 and ADCs such as Enhertu and Trodelvy in stroma rich tumors including pancreatic cancer, TNBC, and ovarian cancer models.
  • The company is establishing collaborations with ADC companies and welcomes more collaborations against deadly high stroma tumors.

Olatec Therapeutics Announces Publication of Preclinical Research on Oral NLRP3-Specific Inhibitor Dapansutrile in Pancreatic Ductal Adenocarcinoma

Retrieved on: 
Tuesday, October 3, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, PDAC, Inflammation, Pancreatic cancer, Survival, Cancer, NLRP3, CD8, Patient, TME, Mouse, Therapy, Phenotype, Tumor microenvironment, Pancreatic tumor, Metastasis, Pharmaceutical industry

Olatec Therapeutics LLC (Olatec) , a leader in the developing class of oral selective NLRP3 inhibitors, today announced a publication in Cancer Research Communications showing a reduction in tumor progression with dapansutrile as a monotherapy, resulting from inhibition of NLRP3/IL-1β pathway in mouse models of pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • Olatec Therapeutics LLC (Olatec) , a leader in the developing class of oral selective NLRP3 inhibitors, today announced a publication in Cancer Research Communications showing a reduction in tumor progression with dapansutrile as a monotherapy, resulting from inhibition of NLRP3/IL-1β pathway in mouse models of pancreatic ductal adenocarcinoma (PDAC).
  • Additionally, the data show that dapansutrile, when administered in combination therapy with gemcitabine significantly increased efficacy of this chemotherapy.
  • PDAC has been reported to constitute ninety percent of all pancreatic cancers and it is the third leading cause of cancer deaths in the US and seventh worldwide.
  • We believe patient outcomes could potentially be improved if the data from our preclinical studies translate in clinic trials.”

PANCREATIC CANCER ACTION NETWORK ANNOUNCES RECORD-BREAKING ANNUAL RESEARCH INVESTMENT, INCLUDING NEW GRANT AWARDS, WHICH WILL ACCELERATE PROGRESS AGAINST PANCREATIC CANCER

Retrieved on: 
Wednesday, August 30, 2023
Pancreatic cancer, KRAS, Risk, Pancreatic Cancer Action Network, Biotechnology, Policy, Survival, Therapy, MBA, Research, Mentorship, Biomarker, Doctor of Philosophy, A1C, Protein, Glycine, Patient, JD, Immune system, Vutrisiran, Biology, Neoplasm, Memory, Pancreatic tumor, Disease, Peripheral nervous system, Pharmaceutical industry, Management, Medical imaging

LOS ANGELES, Aug. 30, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, today announced its largest ever single-year research investment—more than $34 million—which includes its large-scale scientific and clinical initiatives and nine new grants.

Key Points: 
  • These funds support PanCAN's priority of finding an early detection strategy and accelerating treatment options for people with pancreatic cancer.
  • "This year marks 20 years of PanCAN awarding research grants – and over that time we have established ourselves as the catalyst for change in the pancreatic cancer community.
  • Since 2003, PanCAN has awarded 236 grants to scientists at 78 institutions around the country, building a comprehensive pancreatic cancer research community.
  • In 1999, when the Pancreatic Cancer Action Network (PanCAN) was founded, there were only a handful of scientists focused on pancreatic cancer, and research funding opportunities were scarce.

Kansas City University Recognized for "Groundbreaking" Pancreatic Cancer Research

Retrieved on: 
Thursday, August 24, 2023
Free Radical Biology and Medicine, Pancreatic cancer, Biochemistry, DNA, Human, ICRR, Radiation, University, Bioorganic chemistry, Cancer, Dicarboxylic acid, University of California, Research, Toxicity, Cell, Doctor of Philosophy, Associate, Acipimox, Hyperlipidemia, Student, Journal, Risk, Kansas City University, Master of Science, Biology, Growth, KCU, International Congress on Tuberculosis, Environment, Tumor microenvironment, Sarsour, Safety, Pancreatic tumor, Radiation Research, Pfizer, Pharmaceutical industry, Medical imaging, Vaccine, Medicine

KANSAS CITY, Mo., Aug. 24, 2023 /PRNewswire/ -- Kansas City University (KCU) Associate professor Ehab Sarsour, MSc, PhD, and student-researchers have discovered a new and promising avenue for treating pancreatic cancer by treating the tumor microenvironment by repurposing a drug designed for hyperlipidemia.

Key Points: 
  • KANSAS CITY, Mo., Aug. 24, 2023 /PRNewswire/ -- Kansas City University (KCU) Associate professor Ehab Sarsour, MSc, PhD, and student-researchers have discovered a new and promising avenue for treating pancreatic cancer by treating the tumor microenvironment by repurposing a drug designed for hyperlipidemia.
  • The research found that pancreatic cancer cells receive support from fatty acids that feed pancreatic cancer tumors and protect them from radiation and chemotherapy.
  • As humans age, the risk of cancer increases due to metabolic change dependent on fatty acids and lipids Fatty acids help pancreatic tumor cells resist radiation and chemotherapy.
  • "Katiana' s research work resulted in making cancer cells weaker, depriving them of nourishment from the microenvironment they were in that enables them to be resilient," said Sarsour.

AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer

Retrieved on: 
Wednesday, August 9, 2023
Pancreatic cancer, Database, Human, Pancreatic tumor, Cancer, Lung cancer, Immunotherapy, HIV disease progression rates, Patient, Nature, Annual report, Intel, SpaceX CRS-16, Drug discovery, Diagnosis, LOS, UCLA, Letter, Combination, Cube, Medical imaging, Pharmaceutical industry, Oracle, NVIDIA

The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.

Key Points: 
  • The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.
  • Dr. Anahid Jewett is a leading cancer immunotherapy researcher at UCLA who has conducted independent, pivotal studies with Renovaro’s technology in different animal models.
  • For more information on Renovaro Biosciences Inc. go to their website at www.renovarobio.com .
  • For more information on GEDi Cube Intl LTD, go to their website at www.gedicube.com .